Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.50
- Piotroski Score 2.00
- Grade Buy
- Symbol (TSVT)
- Company 2seventy bio, Inc.
- Price $4.71
- Changes Percentage (2.62%)
- Change $0.12
- Day Low $4.61
- Day High $4.72
- Year High $6.40
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.35
- Trailing P/E Ratio -0.9
- Forward P/E Ratio -0.9
- P/E Growth -0.9
- Net Income $-217,570,000
Income Statement
Quarterly
Annual
Latest News of TSVT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
Analysts have upgraded revenue forecasts for 2seventy bio, Inc., leading to a 11% share price increase. Despite a projected revenue decline, reduced losses indicate progress towards profitability. How...
By Yahoo! Finance | 2 months ago
